Welcome to our dedicated page for Adaptimmune Therapeutics Plc SEC filings (Ticker: ADAPY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adaptimmune Therapeutics plc (ADAPY) has used U.S. Securities and Exchange Commission processes to manage the trading and regulatory status of its American Depositary Shares. The company reports that its ADSs were voluntarily delisted from Nasdaq and that it initiated deregistration under Section 12(b) of the Securities Exchange Act of 1934 by filing a Form 25 and a Form 15.
According to Adaptimmune, the Form 25 was filed to remove its ADSs from listing on Nasdaq, and the subsequent Form 15 filing suspended the company’s obligation to file periodic reports under the Exchange Act. These steps are described as part of an effort to reduce public company costs while the ADSs continue to be quoted on the OTC Pink Limited Market under the symbol ADAPY.
On this SEC filings page for ADAPY, users can review historical and status-related filings associated with Adaptimmune’s ADSs, including documents that address delisting and deregistration. For investors analyzing the company’s regulatory history, filings related to the Nasdaq delisting, Exchange Act registration status and any associated disclosures provide insight into how Adaptimmune has adjusted its reporting obligations.
Stock Titan enhances access to these filings with AI-powered summaries that explain the purpose and implications of key documents, such as Forms 25 and 15. Real-time updates from the EDGAR system, combined with simplified explanations, can help readers understand how changes in listing status, reporting requirements and corporate structure affect Adaptimmune’s presence in U.S. public markets and its obligations as an issuer.
Adaptimmune Therapeutics plc received a Schedule 13G from Long Focus Capital Management, LLC and John Helmers regarding its American Depositary Shares, each representing 6 ordinary shares. As of the close of business on December 31, 2025, the filing reports beneficial ownership of 0 ADS, representing 0% of the class, with no sole or shared voting or dispositive power.
The securities referenced were purchased in client accounts managed by Long Focus, and no individual client owns more than 5% of the class. The filers certify the holdings are in the ordinary course of business and not for influencing control of Adaptimmune.